Pelthos Therapeutics (PTHS)
Commercializes topical treatments for molluscum, impetigo, and head lice.
Pelthos Therapeutics Q2 Earnings Call Highlights
Pelthos Therapeutics NYSEAMERICAN: PTHS reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment's July 2025 commercial launch. The company also discussed an accounting restatement related to the fair-value measurement of convertible debt and outlined expected 2027 launches for its complementary products XEPI and XEGLYZE.
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $6.62 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $5.38 per share a year ago.
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026.
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of the close of business on August 4, 2026 are entitled to notice of and to vote at the 2026 Annual Meeting. The Company anticipates filing the Notice of Annual Meeting and proxy statement in early August 2026.
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective when the US market opened on June 29 as part of the 2026 Russell indexes reconstitution.
Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $3.09 per share versus the Zacks Consensus Estimate of a loss of $4. This compares to a loss of $3.2 per share a year ago.
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units dispensed Management will host a conference call today, May 14, 2026, at 8:30 a.m. ET DURHAM, N.C.
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report first quarter 2026 financial results on Thursday, May 14, 2026.
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease
Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $3.95. This compares to a loss of $3.2 per share a year ago.
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025.
Pelthos Therapeutics to Present at 38th Annual ROTH Conference
DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. Pacific Time.
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquired Xeglyze® (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million.
Pelthos Pharmaceuticals: Off To A Strong Start With Zelsuvmi, Continued Sales Growth Is Likely
Pelthos Pharmaceuticals has launched Zelsuvmi, the first at-home FDA-approved treatment for molluscum contagiosum, showing strong initial sales growth. PTHS reported $7.1 million net revenue in its first commercialization quarter, prompting an expansion of its sales force. The company targets breakeven by end-2026, with peak revenue projections of $175 million likely conservative given rapid prescription uptake and market size.
Pelthos Therapeutics Inc. (PTHS) Q3 2025 Earnings Call Transcript
Pelthos Therapeutics Inc. ( PTHS ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Mike Moyer Scott Plesha - CEO, President & Director Sai Rangarao Francis Knuettel - Chief Financial Officer Conference Call Participants Jeffrey Jones - Oppenheimer & Co. Inc., Research Division James Molloy - Alliance Global Partners, Research Division Presentation Operator Greetings, and welcome to the Pelthos Therapeutics Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note, this conference is being recorded.